ClinicalTrials.gg
RecruitingNCT07461779Updated Mar 10, 2026

Effect of Oxygen Administration in the Non-dependent Lung on Postoperative Complications After Lung Surgery

A Phase 4 interventional study of Medicinal gas - oxygen (Nippon Gases 200 bar) and CPAP in Lung Resection Surgery and Anesthesia General, sponsored by Francisco Andres de la Gala. Recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-10.

Sponsored by Francisco Andres de la Gala · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Jan 2025, registered Nov 2025).
  • Started Jan 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
177
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 69 studies in Postoperative Complications with a site in Spain — 13 open to participants now, 15 under way, 1 of them phase 3. Postoperative Complications · Spain.

Planned enrollment
17th of 32
177 · median 178
Started
2025
with 4 others
Phase 4
4 of 69
1 open now
Primary completion
2026-12
later than 6 of 14 live
Registered
66th of 69
by date
Lead sponsor
2 of 69
Francisco Andres de la Gala

Among the 69 studies in Postoperative Complications with a site in Spain, this one is the 17th largest by planned enrollment of the 32 interventional ones that give a count, is one of 5 that started in 2025, is one of 4 in phase 4, reaches primary completion later than 6 of the 14 other live ones, and was the 66th registered.

Postoperative Complications

1,343 studies on the registry are indexed under Postoperative Complications; 314 are open to participants now.

Browse Postoperative Complications studies →

Open to participants now

13 of the 69 studies in Postoperative Complications with a site in Spain are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 200 Postoperative Complications studies recruiting now, 126 (63%) set no upper age limit and 31 (16%) stop at 75 or younger; 24 take children under 18; 25 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Postoperative Complications with a site in Spain, or all of them as a file.
02

Study summary

The purpose of this study is to analyze the effectiveness of apneic oxygenation and CPAP applied to the non-dependent lung during pulmonary resection surgery in reducing inflammatory response, ischemia-reperfusion injury, and postoperative complications. We will conduct a randomized, controlled, and blinded study in 177 patients with three arms:

  • Control Group: Oxygen therapy according to standard clinical practice
  • Apneic oxygenation group: A probe will be introduced through the lumen of the double-lumen tube (DLT) to administer a continuous source of oxygen without any mechanism that generates airway pressure.
  • CPAP Group: Continuous positive airway pressure with 3-5 L/min oxygen flow and 2 cm H2O pressure delivered via a Mapleson system.

Inflammatory mediators in blood and in both lungs will be measured intraoperatively and 24 hours after surgery. Patients will be followed from hospital admission until discharge and again 30 days after surgery to evaluate the postoperative course, particularly the occurrence of complications according to the revised Clavien-Dindo classification for thoracic surgery, as well as other relevant clinical outcomes.

Read the detailed description

Surgical interventions, particularly lung resection, provoke a significant inflammatory response at both local and systemic levels, characterized by hyperemia and increased vascular permeability. Thoracic surgery requiring one-lung ventilation (OLV) leads to complications such as intraoperative hypoxemia and an exaggerated pulmonary inflammatory response, threatening patient stability. Hypoxemia-commonly defined as SpO2 \< 85-90% or PaO2 \< 60 mmHg-is frequent and increases the risk of complications such as arrhythmias, cognitive dysfunction, pulmonary hypertension, and renal failure, particularly in patients with comorbidities. The difficulty in defining a precise threshold for complications reflects that oxygen deprivation-related tissue hypoxia depends on the balance between oxygen supply and consumption, which is influenced by individual variables such as cardiovascular function and pre-existing conditions.

To mitigate hypoxemia during OLV, several strategies have been implemented. The most common are increasing FiO2 and applying continuous positive airway pressure (CPAP), which significantly improves arterial oxygenation. However, higher pressures may hinder surgical manipulation due to anatomical distortion. Currently, low-pressure CPAP (around 2 cmH2O) is recommended because it provides oxygenation benefits without interfering with the surgery, although clinical evidence remains limited. Apneic oxygenation has also been proposed: oxygen is administered without positive pressure, taking advantage of the fact that during apnea oxygen can diffuse into the alveoli down pressure gradients, sustaining arterial oxygenation even with collapsed lung regions. This technique can prolong safe apnea time, reduce hyperoxia risk, and maintain oxygenation while minimizing interference with surgical exposure.

Conversely, OLV triggers a strong inflammatory response caused by tissue injury, atelectrauma, volutrauma, and barotrauma in the dependent lung, along with oxidative stress damage in the non-ventilated lung. Prolonged exposure to high FiO2 contributes to lung injury through oxidative mechanisms similar to those in adult acute respiratory distress syndrome. Re-expansion of the collapsed lung after OLV also releases free radicals, exacerbating ischemia-reperfusion injury, especially in lung cancer patients who may have reduced antioxidant capacity. Activation of the NLRP3 inflammasome, stimulated by reactive oxygen species, promotes proinflammatory cytokine production, contributing to tissue damage, increased capillary permeability, and pulmonary edema, thereby raising the risk of postoperative respiratory failure.

Although advances have been made, evidence is limited regarding the impact of apneic oxygenation on reducing inflammation, oxidative stress, and postoperative complications in lung surgery. However, studies in other surgeries suggest this technique could decrease inflammatory markers and improve oxygenation without impairing surgical exposure. Therefore, this study aims to evaluate and compare the efficacy of apneic oxygenation and CPAP applied to the nondependent lung during lung resection surgery, focusing on reducing inflammatory response, ischemia-reperfusion injury, and postoperative complications, and thus providing evidence to improve perioperative strategies for these patients.

Hypothesis: Maintaining a continuous oxygen flow to the nondependent lung, with minimal pressure (CPAP) or none at all (apneic oxygenation), during OLV will reduce alveolar hypoxia in that lung, thereby attenuating ischemia-reperfusion-related lung injury and improving the postoperative course. Additionally, it will reduce the incidence of intraoperative hypoxemia and permit use of lower oxygen concentrations to the dependent lung, which may further improve prognosis.

03

Conditions studied

  • Lung Resection Surgery
  • Anesthesia General

Keywords

  • Postoperative complications
  • Thoracic surgery
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients of both genders undergoing lung resection surgery in the Thoracic Surgery Department at Hospital General Universitario Gregorio Marañón
  • Lung isolation using a double-lumen tube (DLT)
  • Scheduled surgery
  • Patients able and willing to give written
  • Patients over 18 years old and legally competent

Exclusion criteria

Exclusion Criteria:

  • Patients with evidence of pulmonary bullae
  • Pregnancy or breastfeeding
  • Blood transfusion within 10 days prior to surgery
  • Treatment with or within 3 months prior to surgery
  • Patient refusal to participate
  • Prior contralateral thoracic surgery
  • Robotic surgery
  • Pneumonectomy
  • Enrollment in another clinical trial
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
177 participants (estimated)

Study arms

  • Active comparator
    Control group

    Oxygen therapy according to standard clinical practice. The nondependent lung (surgical) will be connected to ambient air by opening the lumen of the double-lumen tube (DLT) directed towards that lung

    Procedure: Oxygen therapy according to standard clinical practice

  • Experimental
    CPAP Group

    Continuous positive airway pressure with 3-5 L/min oxygen and 2 cmH2O pressure delivered via a Mapleson system

    Device: CPAP

  • Experimental
    APNEIC OXYGENATION group

    A probe will be introduced through the lumen of the DLT to deliver a continuous flow of oxygen without any mechanism that generates airway pressure

    Drug: Medicinal gas - oxygen (Nippon Gases 200 bar)

Interventions

  • DrugMedicinal gas - oxygen (Nippon Gases 200 bar)

    Medicinal gas, compressed. Oxygen 99.5% v/v

  • DeviceCPAP

    Continuous positive pressure

  • ProcedureOxygen therapy according to standard clinical practice

    Ambient air connection

06

What researchers measure

Primary outcomes

  1. Postoperative complications

    To compare the proportion of patients in each grade of the revised Clavien-Dindo classification for thoracic surgery across the three study groups

    Time frame: Up to 30 days after intervention

Secondary outcomes

  1. Gas exchange and acid-base balance

    To compare gas exchange and acid-base balance during the intraoperative period and during the first 24 hours postoperatively

    Time frame: Intraoperative period and 24 hours

  2. Degree of interference with surgical exposure (Surgeon Satisfaction Scale on Oxygen Therapy Interference, 1-5)

    Assessed by the surgeon at the end of the procedure using the Surgeon Satisfaction Scale on Oxygen Therapy Interference, an ordinal 5-point scale: 1 = Surgery impossible (change O2 administration method required); 2 = Very difficult technique (no change in O2 administration required); 3 = Considerably more difficult than usual; 4 = Somewhat more difficult than usual; 5 = Similar to usual.

    Time frame: Surgery duration; assessed at end of surgery

  3. Incidence of postoperative pulmonary complications

    To compare de incidence of postoperative pulmonary complications among the three study groups

    Time frame: Up to 30 days after intervention

  4. Special Care Units stay

    To compare the length of stay in Special Care Units among the three study groups

    Time frame: Up to 30 days after intervention

  5. Readmisions to Special Care Units

    To compare the number of readmissions to Special Care Units among the three study groups

    Time frame: Up to 30 days after intervention

  6. Hospital Stay

    To compare the average hospital stay (measure in days) among the three study groups

    Time frame: Up to 30 days after intervention

  7. Hospital readmission

    To compare hospital readmissions among the three study groups

    Time frame: Up to 30 days after intervention

  8. Inflammatory biomarkers in blood and bronchoalveolar lavages

    To evaluate the inflammatory response measured in blood and bronchoalveolar lavages during the first 24 hours postoperatively in the three patient groups. Blood samples and bronchoalveolar lavages will be taken at the beginning of surgery, at the end of one-lung ventilation, and at 24 hours postoperatively

    Time frame: Up to 24 hours after intervention

  9. New molecules involved in oxidative stress

    Identification of new molecules involved in oxidative stress: Plasma concentrations of oxidative stress markers (SOD, MDA, MPO, CP, ROS index, plasma thiols). All biochemical determinations will be performed by spectrophotometry using validated specific kits. Samples collected pre-intervention and at 2, 6 and 24 hours post-intervention.

    Time frame: Up to 24 hours after intervention

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Dec 2026, 23 months after the start.

Of 45 non-industry phase 4 interventional studies under Postoperative Complications, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 32. This study's planned 23 months is close to that.

Counting every sponsor, half of 46 studies reached it within 25 months; a quarter within 19 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2025
First posted
Mar 10, 2026
StartActual
Jan 27, 2025
Primary completionEst.
Dec 30, 2026
CompletionEst.
Mar 30, 2027
Last update
Mar 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07461779
Lead sponsor
Francisco Andres de la Gala
Collaborators
Instituto de Salud Carlos III
Responsible party
Francisco Andres de la Gala (MD, PhD, Hospital General Universitario Gregorio Marañon) — Sponsor-investigator
First posted
Mar 10, 2026
Start date
Jan 27, 2025
Primary completion
Dec 30, 2026 (estimated)
Completion
Mar 30, 2027 (estimated)
Last update
Mar 10, 2026

Study contacts

Francisco de la Gala, MD, PhD
Contact
francisco.gala@salud.madrid.org
+34915868367
Ignacio Garutti, MD
Contact
ignacio.garutti@salud.madrid.org
+34915868367
Francisco de la Gala, MD, PhD
principal investigator · Hospital General Universitario Gregorio Marañón

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion